From Innovation to Adoption: Key Themes from the ABHI UK HealthTech Conference 2026
The 2026 ABHI UK Healthtech Conference took place in London over 9 and 10 November and was attended by data protection specialist, Sarah O’Brien, and intellectual property specialists, Helen Conlan and Jon Edwards.
------------------------------------------------------------------------------------------------------------------------
The ABHI UK HealthTech Conference 2026 brought together leaders from industry, government, and the NHS to consider the changing environment for HealthTech in the UK. As the UK seeks to strengthen its position as a global destination for HealthTech innovation, a recurring theme was clear: the challenge for the sector is not simply developing innovative technologies, but creating a system capable of evaluating, adopting and scaling new technologies into widespread and routine NHS use.
Regulation: Enabling Innovation While Maintaining Trust
A significant focus was the evolving regulatory framework for medical devices, including software as a medical device and AI-enabled technologies. As MedTech becomes increasingly software-driven and data-dependent, the regulatory environment is adapting accordingly. For manufacturers and developers, regulation should be seen as a lifecycle consideration rather than simply a hurdle to overcome prior to launch.
This was a key theme explained on day one of the ABHI conference, which had a strong regulatory focus and placed particular emphasis on the work of the National Commission into the Regulation of AI in Healthcare. AI-enabled technologies present distinct regulatory challenges compared with more conventional medical devices and technology, not least because they can evolve over time and require ongoing assessment of their performance, risks and use in real-world clinical settings.
The Commission’s research and work sits within the Government’s wider ambition, reflected in the 10-Year Health Plan for England and the Life Sciences Sector Plan, to make the NHS the most AI-enabled healthcare system in the world. Bringing together clinical leaders, patient representatives, industry and regulators, the Commission concluded that fundamental changes to the existing regulatory framework are needed if clinicians and patients are to benefit more quickly from AI technologies while maintaining safety and public trust. The Government’s response to the Commission’s report, published on 6 October 2026, accepted all 44 of the Commission’s recommendations.
Broadly, the Commission’s recommendations include moving towards a proportionate, risk- and lifecycle-based regulation, strengthening post-market assurance, clarifying responsibilities across the healthcare system, and improving regulatory transparency and predictability. The next stage will be translating the Commissions’ recommendations into practice, working alongside the MHRA and other bodies across the health system, such as the UK Centre of Excellence for Regulatory Science in AI & Digital Health (CERSI-AI).
The Government’s response can be viewed here: https://www.gov.uk/government/publications/government-response-to-the-national-commissions-recommendations-on-the-regulation-of-ai-in-healthcare/government-response-to-the-national-commissions-recommendations-on-the-regulation-of-ai-in-healthcare
Cybersecurity and Software Concerns
Software and AI medical devices are playing a growing role in healthcare infrastructure. Examples include AI-enabled triage, diagnostics and clinical decision-support tools, which offer opportunities to increase capacity and efficiency. As much as AI-enabled medtech presents opportunities, however, just as many questions and challenges are raised around regulatory responsibility, output quality, system readiness, trust and security.
One particular risk highlighted in the conference is that the increasing use of connected software and AI brings cybersecurity risks into sharper focus. Building cyber resilience into products from the outset will be increasingly important, both to protect sensitive health data and ensure the safety and continuity of medical technologies - from connected implants to connected infrastructure upon which patients and clinicians rely.
Market Access: Bridging the Adoption Gap
One of the strongest themes from the conference was the gap between the rate and volume of HealthTech innovation compared to the more limited examples of successful NHS implementation and adoption. The UK does not suffer from a shortage of innovative technology. The difficulty is moving successful products beyond pilots and individual NHS organisations into routine use at scale.
Fragmented procurement, repeated approval processes, prolonged pilots and unclear demand signals were all cited as reasons for failed and slow adoption. For growing HealthTech businesses, delay can also undermine investment at precisely the point at which capital is needed to scale.
The message for developers was clear - start with the healthcare problem and work backwards. Successful technologies need a clear demand signal: an identifiable NHS use case, credible supporting evidence and the ability to address genuine patient, clinician or system needs. New technology developed without a clearly identified clinical or commercial need can struggle to find a market, however impressive the underlying science. Commercial strategy and product development need to move together from the beginning.
The goal is to balance the desire to achieve faster access to innovative technologies whilst simultaneously maintaining patient safety and public confidence. Evidence and transparency remain central to this. Demonstrating that a technology works is only part of the equation: developers increasingly need to show that new technology can be trusted, integrated into existing clinical pathways and deliver meaningful benefits in real-world use.
Creating Clearer Pathways to Adoption
The National HealthTech Access Programme (NHAP), launched earlier this year, represents an important attempt to address some of these challenges. NHAP brings together NICE, the DHSC, NHS England, the MHRA and the OLS to create a more coordinated route for selected high-impact technologies to achieve national adoption.
By extending NICE's technology appraisal approach to incorporate health technologies means that, like with medicines, a small selection of high-impact technologies will be reimbursed and enjoy wider NHS availability.
Intellectual Property: Protecting Value as HealthTech Scales
Whilst intellectual property was not a headline theme of the conference, it sits behind many of the issues discussed. A well-structured IP portfolio can support fundraising, licensing and collaboration for developers of new technologies. It can also provide valuable market space and exclusivity and give investors greater confidence that the value they are backing is safeguarded as the business scales. An effective IP strategy goes hand in hand with product development and commercial strategy. It should therefore develop alongside the product and commercial strategy from the outset.
Taking HealthTech from bench to bedside typically involves a wide network of collaboration between innovators, manufacturers, healthcare providers, clinicians, research institutions and commercial partners. Businesses therefore need to understand both what IP protects their competitive advantage and who owns it. Maintaining a clear chain of title and evidence of ownership, particularly in relation to employees, consultants and collaboration partners, becomes increasingly important as development progresses.
These considerations are particularly relevant for HealthTech incorporating software and AI, where valuable IP may reside in proprietary source code and algorithms. Where software incorporates third-party and open-source components, it is vital for businesses to understand the extent of such components and the applicable licence terms, particularly where copyleft obligations could require the disclosure or licensing of proprietary source code when software is distributed in certain ways. Unmanaged open-source dependencies can create risk for trade secret protection, commercialisation and, ultimately, the value attributed to the technology by investors or potential partners.
As medical devices become increasingly software-driven, connected and AI-enabled, the boundaries between traditional medical-device engineering and the digital technology sector are rapidly disappearing. This convergence creates significant opportunities for innovation but also requires developers to navigate a complex and wider array of IP, medical-device regulation, cybersecurity and data protection laws.
From Innovation to Scalable HealthTech
The overarching message was that innovation alone is not enough.
Successful HealthTech increasingly requires developers to align technology, evidence, regulation, clinical demand, reimbursement and commercial strategy from the outset. The businesses best placed to scale will be those that can demonstrate not simply that their technology works, but that it solves a recognised healthcare problem, delivers measurable value and has a credible route into routine adoption.